

Next Generation Biologics Manufacturing: Delivering the Vision

Presented by Timothy Alosi





oft. EMEA USERS CONFERENCE 2017 LONDON

#OSISOFTUC ©2017 OSIsoft, LLC

The driver behind Biogen's Next Generation Manufacturing

Alzheimer's Disease

5.3 million people in the US, and *25 million* worldwide live with Alzheimer's

Alzheimer's is the 6th leading cause of death in the US

http://alz.org

Aducanumab Phase 1b Results

"Aducanumab demonstrated an acceptable safety profile and patients treated with aducanumab experienced a dose- and time-dependent, statistically significant reduction of brain amyloid plaque, which is believed to play a key role in the development of the symptoms of Alzheimer's disease. Additionally, a dose-dependent, statistically significant effect of slowing clinical decline was observed in the aducanumab study arms."

http://for.tn/1QkEiAQ



Biogen's Next Generation Manufacturing

The Next Generation Manufacturing will be the intersection point and realization of key Biogen initiatives that have been developing over the past several years:

Initiatives

- 3X Technology
- Next Generation
 Automation
- Real-time Release
- Enhanced Process Control / PAT
- Integrated work teams
- Repeatability via Bio-Manufacturing Cell
- Through-put analysis
- Sustainability

Guiding Principles

- Process / Process equipment is the critical path Not support equipment
- **Real time data** availability that enables product impact decisions to be made on the floor
- The NGM facility should produce drug substance (DS) at 1/5
 the cost of our other facilities
- Ensure **repeatability**, **dependability** for delivering to our patients (*Bio-Manufacturing Cell Concept*)
- Ensure site atmosphere is an enjoyable place to work lockers, natural light in process area, collaboration space on the floor, lab space on the floor
- Minimize Manpower for material flow

Biogen's Next-Generation Facility

- Under construction in Solothurn, Switzerland
- Start of production in 2019
- Bio-Manufacturing Cells (BMC)
 - Initial: 2 BMCs, ~10 Metric Tons
 - Expandable to 35 Metric Tons
- 3X platform up to 15 g/L CC titer
- 55,000 m² in Phase 1
- Integrated Execution Systems





Reaching 1 Million Patients by 2020

"Act as if a million patients are counting on us to perform today. Because they are!"

Every day and every batch counts!

Limitations in legacy manufacturing

Output of manufacturing process per unit time

Requirement to wait for testing and to react to process variation

Manual transfer of information between systems, waiting for batch release



Driving the process via Reliable and Consistent Control

Strategic Intent: Well understood and controlled process to drive Robustness & Consistency, Improved Efficiency, and Real-time Quality



Legacy Bio Manufacturing Process

Next Generation Manufacturing



Enhancing Controls to reduce variability and improve performance

Raw Material Control

- Achieve prospective Raw Material control through Raw Material screening and genealogy
- Minimize internal Raw Material testing using Rapid ID and electronic data exchange.

Process Control

- Bioreactor controlled through inline instruments, sampling for process control eliminated
- Adaptive process control levers developed (e.g. HMW FF control)
- Plant floor and lab execution by recipe (S88)

Quality Control

- "Right time release" to ensure testing is not rate limiting
- Testing completed as early in the process as possible

Models

- Models for PQ prediction and consistency assessment wherever feasible
- Model capabilities grow and evolve as additional experience is gained
- Leverage established ASTM guidance and previous BIIB experience for model implementation and LCM





Direct Dispense: Raw Material Lead Time Reduction





Delivering a Robust and Adjustable Process with Advanced Process Controls



0

0

©2017 OSIsoft. LLC

Next Generation Drug Substance CofA

Current State		
Category	What	Where
General	рН	QC Lab
	Osmolality	
	Color (visual)	
	Turbidity (visual)	
Quantity	Protein Conc by RI	
Identity	ICIEF & Binding Assay	
Purity/Impurities	UPLC-SEC	
	Non-Reducing CE-SDS	
	Imaging Capillary IEF	
Biological Activity	Binding Assays	
Safety	Bioburden (plates)	
	Endotoxin (turbidimetric)	
	In-Vitro Adventitious Virus	

Future State			
Category	What	Where	
General	Inline pH	In-line	
	Inline Conductivity		
	Color by HunterLab	At-line	
	Turbidity Meter		
Quantity	Protein Conc by SoloVPE		
Identity	Dot Blot ID		
Purity/Impurities	UPLC SEC		
Safety	Endotoxin by EndoSafe		
Purity/Impurities	LC/MS Peptide Map	High Tech Lab	
Biological Activity	Binding w/ Automation		
Safety	Bioburden by GrowthDirect		
	NGS for Adventitious Virus		

Self-sufficient right-time testing and exceptionsbased review for instant disposition



Next Generation Manufacturing depends on Next Generation Execution Systems

Aducanumab requires delivering high quality products at a higher volume than we have ever done before

NGM delivers the technology to meet this challenge but require business systems that are not rate limiting

Limitation



Output of manufacturing process per unit time



- Requirement to wait for testing and to react to process variation
- Manual transfer of information between systems, waiting for batch release

Resolution

→ 3X Platform: Higher titer, faster upstream and downstream processing



- APC: Results on the manufacturing floor, real time adaptation, CofA by time DS is frozen
- BES: All data electronic and shared real time, release by exception with integrated systems

Takeaway: Realizing the full benefits of the new 3X/APC platform is not possible without integrated business execution systems



Next Generation Manufacturing is driving the evolution of the Biogen Execution Systems

Current State:

- Manufacturing relies on paper records and manual activities
- Records are reviewed in their entirety for batch release
- Test data and supporting documentation transcribed



Future State:

- Integrated systems make information available real time
- Batches are released by exception
- Transcription of data is eliminated
- Reduction in time required and error





- I. Eliminate Manual Activities
- 2. System to System Interfaces
- 3. Data Rich Environment





Building a strong foundation with Common Context

CHALLENGE

Inconsistent context across systems and work processes make it extremely difficult to use data easily and effectively.

It is *challenging and time consuming* to introduce context post-execution with a risk of inconsistent results

Breaking down this barrier unlocks tremendous value from the data!



Capturing a single version of truth enables critical business processes



Benefits

Regulatory

Real-Time Review By Exception reduce time to release batches

CHALLENGE

Current regulations require that we actively **review** computerized **audit trails** to detect abnormal execution of the manufacturing process **prior to product release**.

Computerized systems generate a significant amount of logs and **only a small percentage** of the entries are **pertinent** ("needle in a haystack"), making **manual review time consuming and error prone.**





Enabling Real-Time predictive modeling and advanced process control

CHALLENGE

Biologics manufacturing processes are **inherently variable**, causing yield and quality issues.

Multi-Variate Predictive models can drive improved control but are challenging to generate without the correct data to train the model and the correct context to launch the model, and robust real-time data to provide timely effect.



Driving continuous improvement via Process Trending, Optimization and Quality Event Support

CHALLENGE

There are **many sources of data** generated across the Enterprise from the manufacturing process.

Effective analysis **requires consistent context** and the ability to easily locate and join data

A tremendous amount of data is necessary to optimize the process via statistical and machine learning techniques.





Enterprise access and templates to achieve global operational support, system integration, reports, and KPI's

CHALLENGE

Security requirements protecting the manufacturing systems creates a barrier to accessing and leveraging data widely beyond the shop floor.

Developing **common analytics** and KPIs **across the enterprise** is hindered by inconsistent data and details, making it hard to compare across sites



Next Generation Manufacturing

Deliver meaningful therapies for 1,000,000 patients with Alzheimer's Disease by 2020 at 1/5 the cost of traditional Biologics Manufacturing.





BUSINESS CHALLENGES

- Improve the manufacturing process output per unit time
- Reduce the wait time for testing and need to react to process variation
- Eliminate manual transfer of information between systems, Slowing batch release

SOLUTION

- Deploy our 3X Process Technology, Advanced Controls, and PAT
- Deliver smart, integrated systems and with efficient work processes.
- Deliver a data-rich
 environment

RESULTS AND BENEFITS

- 50% reduction in time waiting for test results
- 70% reduction in batch exceptions
- 78% reduction in batch review time
- A high performing, robust and adjustable process

Timothy Alosi <u>Tim.Alosi@Biogen.com</u> <u>https://www.linkedin.com/in/timalosi/</u> Head – Data Analytics Biogen

Acknowledgements: Rob Guenard, Canping Jiang, Jim Kenyon, Greg Pittman, Jyotika Sharma, Michael Farrow, Dan Hill, Roland Zhou, Gus Green, Dan Keelor, Curt Coury, Dave Burke, Jordan Croteau, Matt Haines





Questions

Please wait for the **microphone** before asking your questions

State your name & company



Complete the Online Survey for this session



Download the Conference App

View the latest agenda and create your ownMeet and connect with other attendees

Search OSIsoft in the app store







